Özet:

Objective: Inflammatory bowel disease encompasses two major form: Crohn's disease and ulcerative colitis. The Crohn's Disease Activity Index is used to determine the severity of disease activity in patients with Crohn's disease. On the other hand, the Truelove-Witts activity index is used to determine the severity of disease activity in patients with ulcerative colitis. Adalimumab and infliximab are biological agents used in the treatment of patients with inflammatory bowel disease. The aim of this study is to conduct a retrospective evaluation regarding the response to adalimumab and infliximab treatment in patients with inflammatory bowel disease. Material and Methods: The data of the patients who were over the age of 18, diagnosed with inflammatory bowel disease, and followed up in the Gastroenterology Clinic and Outpatient Clinic of Firat University Hospital between January 2008-April 2019 were assessed. Eighty patients who received adalimumab and infliximab treatment regularly for at least 4 weeks were included in the study. Results: The Crohn's Disease Activity Index of patients who were diagnosed with Crohn's disease, and received adalimumab and infliximab treatment was compared, and it was found that it was significantly lower after the treatment (p <0.05). Truelove and Witts Activity Index of patients who were diagnosed with Crohn's disease, and received adalimumab and infliximab treatment were compared before and after the treatment, and it was found that it was significantly lower after the treatment (p <0.05). Conclusion: The results showed that the recovery rate was %83,3 in crohn's disease and %84,6 in ulcerative colitis patients. Adalimumab and infliximab treatment was effective on the healing of active disease in patients with inflammatory bowel disease. It was also concluded that although the safety of adalimumab and infliximab was high, but few allergy, lymphadenopathy, and leukopenia side effects were observed.

Anahtar Kelimeler: